Roche snags an FDA ap­proval for an ad­vanced melanoma drug cock­tail — but it's up against some fierce com­pe­ti­tion

Roche’s PD-L1 in­hibitor Tecen­triq snagged an FDA ap­proval to treat cer­tain ad­vanced melanoma pa­tients in a three-drug cock­tail, pro­vid­ing an­oth­er op­tion for pa­tients with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER